Clinical Trials Browser

Phase 1/2 × Multiple Myeloma × 30 days × Clear all

NCT04973605 2026-04-22

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT06876142 2026-04-22

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

Phase 1/2 Suspended

Multiple Myeloma

NCT05392946 2026-04-21

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT03761108 2026-04-20

LINKER-MM1

Phase 1/2 Recruiting

387 enrolled 2 FDA

Multiple Myeloma, Recurrence

NCT04822337 2026-04-16

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Phase 1/2 Active not recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05434689 2026-04-15

COMMANDER

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT07455851 2026-04-15

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT03192397 2026-04-14

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Phase 1/2 Active not recruiting

35 enrolled 19 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Graft vs Host Disease, Hodgkin Disease, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT06669247 2026-04-13

COSTIMM

Phase 1/2 Recruiting

Multiple Myeloma

NCT07463807 2026-04-13

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT07523555 2026-04-13

ADAPT-HEM

Phase 1/2 Recruiting

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Leukemia, Plasma Cell, Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01054196 2026-04-08

Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

Phase 1/2 Active not recruiting

52 enrolled 15 charts

Multiple Myeloma

NCT05850234 2026-04-06

DURGA-1

Phase 1/2 Recruiting

Multiple Myeloma

NCT01502085 2026-04-03

RZD

Phase 1/2 Completed

25 enrolled 5 charts

Multiple Myeloma

NCT02681302 2026-04-03

CPIT001

Phase 1/2 Terminated

46 enrolled 13 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT05583617 2026-04-03

PLYCOM

Phase 1/2 Recruiting

Multiple Myeloma

NCT06536413 2026-04-03

ATRA

Phase 1/2 Recruiting

Multiple Myeloma

NCT07116616 2026-04-03

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT07510100 2026-04-03

FUMANBA-04

Phase 1/2 Not yet recruiting

Multiple Myeloma, Recurrence

NCT01242267 2026-04-02

Thal/Mel/Vel

Phase 1/2 Completed

29 enrolled 13 charts

Multiple Myeloma

NCT07181941 2026-03-27

Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT06232044 2026-03-25

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma